Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Horizonte Médico (Lima)
Print version ISSN 1727-558X
Abstract
PINILLA SOGAMOSO, Jorge Luis et al. Differences between the Framingham and D:A:D risk models for cardiovascular risk assessment in HIV-positive patients on antiretroviral therapy: an experience in a Colombian Caribbean population. Horiz. Med. [online]. 2021, vol.21, n.4, e1671. Epub Dec 03, 2021. ISSN 1727-558X. http://dx.doi.org/10.24265/horizmed.2021.v21n4.08.
Objective:
To assess the five- and ten-year cardiovascular disease risk in HIV-positive patients on antiretroviral therapy, using the Framingham risk score and the Data collection on adverse effects of anti-HIV drugs (D:A:D) study.
Materials and methods:
An observational prospective cross-sectional study. HIV-positive patients on antiretroviral treatment from a referral center for HIV patients were included in the study between January 1 and April 30, 2019. A five- and ten-year cardiovascular risk assessment was performed using the Framingham risk score and the D:A:D study. Additionally, both risk models were compared through statistical models.
Results:
The study population consisted of 159 patients with a mean age of 48.90 years ± 9.90. The mean cardiovascular risk according to the five-year Framingham risk score was 2.70 % ± 2.80, the ten-year Framingham risk score was 6.10 % ± 5.70, the five-year D:A:D study was 3.50 % ± 4.10, the ten-year D:A:D study was 6.90 % ± 7.70, and the ten-year Framingham risk score recalculated for Colombia (multiplied by 0.75) was 4.50 % ± 4.20. Using a logistic regression model, it was determined that the ten-year D:A:D study provided the greatest number of variables significantly related to a high cardiovascular risk.
Conclusions:
The study showed a significant difference between the risk models. Both the five- and ten-year D:A:D study provided a better cardiovascular disease risk estimation than the five- and ten-year Framingham model.
Keywords : HIV infections; Models, cardiovascular; Cardiovascular risk; Antiretroviral therapy, highly active; Caribbean region.